Australia markets closed

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.14+0.46 (+5.99%)
At close: 1:00PM EST
8.19 +0.05 (+0.61%)
After hours: 04:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.68
Open7.79
Bid8.10 x 900
Ask8.15 x 1200
Day's range7.69 - 8.34
52-week range7.37 - 94.17
Volume2,189,645
Avg. volume5,019,011
Market cap676.456M
Beta (5Y monthly)N/A
PE ratio (TTM)26.09
EPS (TTM)0.31
Earnings date11 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.67
  • GlobeNewswire

    Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

    BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of

  • Zacks

    Atea (AVIR) Plunges on Termination of Collaboration With Roche

    Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.

  • Motley Fool

    Why Atea Pharmaceuticals Stock Is Sinking Today

    Shares of Atea Pharmaceuticals (NASDAQ: AVIR) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche's (OTC: RHHBY) decision to terminate its involvement in the development of the oral COVID-19 therapy known as AT-527. Atea Pharmaceuticals will reportedly regain full commercial rights to the drug on Feb. 10, 2022.